FDA en­dors­es No­vavax's piv­otal tri­al de­sign for flu vac­cine; Forty Sev­en bags fund­ing for myelodys­plas­tic syn­dromes pro­gram

→ Fol­low­ing a stream of set­backs with its RSV vac­cine, No­vavax is tout­ing some reg­u­la­to­ry progress of an­oth­er can­di­date for a change. The FDA has ap­par­ent­ly green-light­ed the Phase III tri­al de­sign for NanoFlu, its ad­ju­vant­ed, re­com­bi­nant quadri­va­lent flu vac­cine tar­get­ing the el­der­ly (65 or old­er). The tri­al is ex­pect­ed to be­gin in a cou­ple of months and gen­er­ate top-line da­ta in the first quar­ter of 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER